Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
Avendran Naidu appointed Head of Commercial to lead new affiliate
CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia
Sydney, Australia and Düsseldorf, Germany – 22 July 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally.
